Metabolites with SARS-CoV-2 Inhibitory Activity Identified from Human Microbiome Commensals
Journal article published in 2021 by
Frank J. Piscotta,
Hans-Heinrich Hoffmann,
Young Joo Choi 
,
Gabriel I. Small ,
Alison W. Ashbrook,
Bimal Koirala,
Elizabeth A. Campbell,
Seth A. Darst,
Charles M. Rice,
Sean F. Brady
,
Gabriel I. Small ,
Alison W. Ashbrook,
Bimal Koirala,
Elizabeth A. Campbell,
Seth A. Darst,
Charles M. Rice,
Sean F. Brady
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
The continued prevalence of COVID-19 and the emergence of new variants has once again put the spotlight on the need for the identification of SARS-CoV-2 antivirals. The human microbiome produces an array of small molecules with bioactivities (e.g., host receptor ligands), but its ability to produce antiviral small molecules is relatively underexplored.